Snipping Tool Is Getting a Big GIF Upgrade
GIFs remain one of the most popular image formats on the internet, despite their age. They're even natively integrated into most messaging apps. Now, Microsoft is testing the ability to create and export them using Windows's native screenshot and screen recording tool.
In the current version of Snipping Tool, the only GIFs you can export are static, just like a JPG, PNG, or BMP file. However, a new version of the Snipping Tool currently in the Canary and Dev channels lets you save your screen recordings as an animated GIF instead of an MP4 file.
Most common video formats (especially MP4s) are typically smaller for any given video length, but GIFs have a few advantages. They don't require anything special to work—even a device from 2000 could run one natively—and they loop automatically, which is often a plus if you're using a GIF reaction to express something over text.
Actually using the new GIF export function is refreshingly straightforward. On PCs running the correct experimental versions of Windows, all you need to do is press Windows+Shift+R to launch the screen recorder, capture what you'd like, and then click the 'GIF' button in the top right corner.
You're provided a few export options: the ability to name the file and a vague 'quality' setting, which only includes high or low.
That is about as straightforward as it gets, and it certainly beats capturing a recording, then importing that recording into a third-party program to trim up and export as a GIF. The length of a GIF is limited to 30 seconds—any longer than that and Snipping Tool will prompt you to export it in a video file format instead, like MP4.
Though the feature is in its infancy, it would be nice to see an 'Advanced' option that provides a little more granular control over the GIF, like the ability to set the quality a bit more specifically, or an option to set the framerate.
It could be a while. The current GIF export feature is being tested in the Canary and Developer Channels. Generally speaking, features tested in those channels take longer to make it to the live version of Windows than features you see in the Beta channel.
It is also much more common for features tested in those channels to never make it to Windows, though given how practical a native ability to handle GIFs would be, it seems likely that this one will survive.
In the interim, there are a number of screen recording apps that support creating and exporting GIFs. If you like free and open source software (FOSS), ShareX is a pretty good option. It has a huge range of features above and beyond what Windows 11's Snipping Tool currently offers.
ScreenPresso is another popular application that supports exporting GIFs, though it isn't FOSS and has a paid version.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
27 minutes ago
- Business Insider
OpenAI cofounder Greg Brockman says vibe coding has taken away some of the fun parts of being an engineer
OpenAI's cofounder said vibe coding has left human engineers to do quality control. On an episode of Stripe's "Cheeky Pint" podcast uploaded last week, OpenAI's cofounder and president, Greg Brockman, said that AI coding will only get better. But until then, it's taking away some parts of software engineering that he said are enjoyable. "What we're going to see is AIs taking more and more of the drudgery, more of this like pain, more of the parts that are not very fun for humans," Brockman said. He added, "So far, the vibe coding has actually taken a lot of code that is actually quite fun." He said that the state of AI coding has left humans to review and deploy code, which is "not fun at all." Brockman added that he is "hopeful" for progress in these other areas, to the point that we end up with a " full AI coworker" that could handle delegated tasks. Changing engineering landscape Using AI to write code, dubbed " vibe coding" by OpenAI cofounder Andrej Karpathy, has skyrocketed this year. Engineers and novices alike are using tools like Microsoft's Copilot, Cursor, and Windsurf to write code, develop games, and even build websites from scratch. Vibe coding has already started changing how much Big Tech and venture capital value people with software engineering expertise. In March, Y Combinator's CEO, Gary Tan, said that vibe coding is set to transform the startup landscape. He said that what would've once taken "50 or 100" engineers to build can now be accomplished by a team of 10, "when they are fully vibe coders." Earlier this month, Business Insider reported that AI coding is no longer a nice-to-have skill. Job listings from Visa, Reddit, DoorDash, and a slew of startups showed that the companies explicitly require vibe coding experience or familiarity with AI code generators like Cursor and Bolt. Still, some in tech circles say leaning on it heavily is short-sighted and the job is being trivialized. Bob McGrew, the former chief research officer at OpenAI, said that while product managers can make "really cool prototypes" with vibe coding, human engineers will still be brought in to "rewrite it from scratch." "If you are given a code base that you don't understand — this is a classic software engineering question — is that a liability or is it an asset? Right? And the classic answer is that it's a liability," McGrew said of software made with vibe coding. GitHub's CEO, Thomas Dohmke, said that vibe coding may also slow down experienced coders. On a podcast episode released last week, he said that a worst-case scenario is when a developer is forced to provide feedback in natural language when they already know how to do it in a programming language. That would be "basically replacing something that I can do in three seconds with something that might potentially take three minutes or even longer," Dohmke said.
Yahoo
44 minutes ago
- Yahoo
Lake Street: AMT-130 Could Be Game-Changer For ClearPoint
uniQure N.V. (NASDAQ:QURE) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Lake Street Capital reiterated its Buy rating and $30 price target for ClearPoint following uniQure N.V. (NASDAQ:QURE) regulatory update on AMT-130, an experimental gene therapy for Huntington's disease. A team of scientists in lab coats studying a microscope, working on developing gene therapy solutions. uniQure N.V. (NASDAQ:QURE) declared that it has partnered with the FDA to seek an expedited approval process for AMT-130. If the trials go well and the FDA approves it, Lake Street sees AMT-130 as maybe ClearPoint's first 'meaningful partner asset.' ClearPoint provides disposables valued at almost $20,000 for each AMT-130 infusion, suggesting a significant financial benefit associated with the therapy's effectiveness. The FDA's support might result in the approval by the end of 2026, which would have a big effect on ClearPoint's financial standing and confirm its strategic focus on image-guided neurosurgery and gene therapy delivery. According to Lake Street, this regulatory milestone increases clarity on ClearPoint's contribution to the advancement of clinical-stage gene treatments and provides further assurance regarding the clearance timeline for AMT-130. While we acknowledge the potential of QURE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
44 minutes ago
- Yahoo
Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. It presented encouraging three-year follow-up data from their Phase 1 trial of lonvoguran ziclumeran (lonvo-z) in patients with hereditary angioedema (HAE) at the EAACI Congress 2025. A lab scientist peering into a microscope focused on gene editing technology. All 10 patients were free of attacks and treatment for a median of 23 months after receiving a single dose of lonvo-z, which led to a 98% mean reduction in monthly HAE attacks. Positive safety results were maintained across all treatment dosages. The current Phase 3 HAELO trial has a majority of U.S. enrollment and has completed screening ahead of schedule. Intellia Therapeutics, Inc. (NASDAQ:NTLA) plans to launch in 2027 after submitting a BLA in 2026. Lonvo-z (NTLA-2002) is an experimental in vivo CRISPR-based gene editing therapy that targets the KLKB1 gene to prevent HAE attacks. The FDA has designated it as an Orphan Drug and RMAT, while the EMA has designated it as PRIME, among other regulatory classifications. Administered intravenously at doses ranging from 25 to 75 mg, the therapy demonstrated dose-dependent kallikrein protein decrease and long-term efficacy, with no major treatment-related side effects recorded. While we acknowledge the potential of NTLA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
